A Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
Phase of Trial: Phase I/II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs NADPH oxidase gene therapy (Primary)
- Indications Chronic granulomatous disease
- Focus Adverse reactions
- 01 Feb 2018 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 01 Feb 2018 Status changed from suspended to recruiting.
- 25 Sep 2017 Status changed from recruiting to suspended.